Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSP107 in relapsed/refractory AML and MDS
NCT04937166Phase 1Terminated
- Sponsor
- KAHR Medical
- Start
- Jan 2022
- Primary completion
- Apr 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DSP107 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by KAHR Medical. Primary endpoints: Adverse Events at 12 months, Dose Limiting Toxicities at 2 months and 1 more. Started Jan 2022; status: terminated.
02
Drugs
DSP107
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04937166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04937166.